157 related articles for article (PubMed ID: 6539387)
1. In vitro characterization of MAT LyLu: a Dunning rat prostate adenocarcinoma tumor subline.
Wenger AS; Mickey DD; Hall M; Silverman LM; Mickey GH; Fried FA
J Urol; 1984 Jun; 131(6):1232-6. PubMed ID: 6539387
[TBL] [Abstract][Full Text] [Related]
2. Dimethylsulfoxide-induced changes in a rat prostate adenocarcinoma.
Wenger AS; Hall M; Mickey GH; Silverman L; Fried FA; Mickey DD
Prostate; 1985; 6(4):329-41. PubMed ID: 4088948
[TBL] [Abstract][Full Text] [Related]
3. Re: In vitro characterization of Mat LyLu: a Dunning rat prostate adenocarcinoma tumor subline.
Shaw MW; Ablin RJ; Guinan PD; McKiel CF; Rubinstein M
J Urol; 1985 Apr; 133(4):691-2. PubMed ID: 3981732
[No Abstract] [Full Text] [Related]
4. Inhibitory effects of dunning rat prostate tumor fluid on proliferation of the metastatic MAT-LyLu cell line.
Bugan I; Altun S
Asian Pac J Cancer Prev; 2015; 16(2):831-6. PubMed ID: 25684533
[TBL] [Abstract][Full Text] [Related]
5. The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor.
Isaacs JT; Yu GW; Coffey DS
Invest Urol; 1981 Jul; 19(1):20-3. PubMed ID: 7251319
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of protein kinase C-zeta (PKC-zeta) inhibits invasive and metastatic abilities of Dunning R-3327 MAT-LyLu rat prostate cancer cells.
Powell CT; Gschwend JE; Fair WR; Brittis NJ; Stec D; Huryk R
Cancer Res; 1996 Sep; 56(18):4137-41. PubMed ID: 8797581
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin.
Pienta KJ; Naik H; Akhtar A; Yamazaki K; Replogle TS; Lehr J; Donat TL; Tait L; Hogan V; Raz A
J Natl Cancer Inst; 1995 Mar; 87(5):348-53. PubMed ID: 7853416
[TBL] [Abstract][Full Text] [Related]
8. Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells.
Haq M; Goltzman D; Tremblay G; Brodt P
Cancer Res; 1992 Sep; 52(17):4613-9. PubMed ID: 1511429
[TBL] [Abstract][Full Text] [Related]
9. Promotion of metastases by tumor necrosis factor in rats bearing Dunning R3327 MAT-LyLu prostatic cancer.
Iizumi T; Yazaki T; Umeda T; Soma GI
Urol Int; 1993; 51(2):85-8. PubMed ID: 8351760
[TBL] [Abstract][Full Text] [Related]
10. Biometric assessment of prostate cancer's metastatic potential.
Cooper CR; Emmett N; Harris-Hooker S; Patterson R; Cooke DB
World J Urol; 1994; 12(6):304-7. PubMed ID: 7881466
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
Getzenberg RH; Light BW; Lapco PE; Konety BR; Nangia AK; Acierno JS; Dhir R; Shurin Z; Day RS; Trump DL; Johnson CS
Urology; 1997 Dec; 50(6):999-1006. PubMed ID: 9426741
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative and antimetastatic effects of gossypol on Dunning prostate cell-bearing Copenhagen rats.
Chang CJ; Ghosh PK; Hu YF; Brueggemeier RW; Lin YC
Res Commun Chem Pathol Pharmacol; 1993 Mar; 79(3):293-312. PubMed ID: 8480076
[TBL] [Abstract][Full Text] [Related]
13. Metastatic potential and substrate dependence of cell motility and attachment in the Dunning R-3327 rat prostatic adenocarcinoma model.
Mohler JL; Levy F; Sharief Y
Cancer Res; 1991 Dec; 51(24):6580-5. PubMed ID: 1742730
[TBL] [Abstract][Full Text] [Related]
14. Differences in expression of oligosaccharide determinants by phenotypically distinct sublines of the Dunning 3327 rat prostate cancer.
Abel PD; Foster CS; Tebbutt S; Williams G
J Urol; 1990 Sep; 144(3):760-5. PubMed ID: 2388349
[TBL] [Abstract][Full Text] [Related]
15. Immunoregulatory markers in rats carrying Dunning R3327 H, G, or MAT-LyLu prostatic adenocarcinoma variants.
Rubenstein M; Shaw MW; McKiel CF; Ray PS; Guinan PD
Cancer Res; 1987 Jan; 47(1):178-82. PubMed ID: 3491674
[TBL] [Abstract][Full Text] [Related]
16. Intermediate filament expression and the progression of prostatic cancer as studied in the Dunning R-3327 rat prostatic carcinoma system.
Ramaekers FC; Verhagen AP; Isaacs JT; Feitz WF; Moesker O; Schaart G; Schalken JA; Vooijs GP
Prostate; 1989; 14(4):323-39. PubMed ID: 2664736
[TBL] [Abstract][Full Text] [Related]
17. Prediction of metastatic potential by cancer cell motility in the Dunning R-3327 prostatic adenocarcinoma in vivo model.
Doyle GM; Sharief Y; Mohler JL
J Urol; 1992 Feb; 147(2):514-8. PubMed ID: 1732634
[TBL] [Abstract][Full Text] [Related]
18. Establishment and in vivo characterization of multidrug-resistant dunning R3327 rat prostate-carcinoma cell-lines.
Bashir I; Sikora K; Abel P; Foster CS
Int J Cancer; 1994 Jun; 57(5):719-26. PubMed ID: 7910810
[TBL] [Abstract][Full Text] [Related]
19. In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers.
Sarosdy MF; Higdon AL; Demoor CA
J Urol; 1996 Jun; 155(6):2085-9. PubMed ID: 8618341
[TBL] [Abstract][Full Text] [Related]
20. Genomic methylation patterns of the Dunning R-3327 prostate adenocarcinoma system.
Blount LV; Cooke DB
Cancer Lett; 1996 Jan; 98(2):213-8. PubMed ID: 8556711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
